Skip to main content
SpringerLink
Log in

Drug selection for the newly diagnosed patient: When is a new generation antiepileptic drug indicated?

  • ENS TEACHING REVIEW
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract.

Treatment options in epilepsy have increased dramatically since the early 1990s with the introduction of nine new generation antiepileptic drugs (AEDs) (felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin and zonisamide). This makes drug selection much more complicated and challenging. This review discusses drug selection in patients with newly diagnosed epilepsy and in particular the role of new AEDs in this population. The choice of treatment should always be based on a careful comparison of the risk-benefit ratio for the different treatment options and the outcome of such evaluation may be different in patients with new onset compared with chronic epilepsy. Efficacy, tolerability and safety are the main criteria for selection of AEDs and any first line drug for patients with newly diagnosed epilepsy must have demonstrated satisfactory efficacy as monotherapy in that patient population. So far, of the new AEDs only lamotrigine, oxcarbazepine and topiramate have documentation sufficient to be granted licence for use as monotherapy in most European countries. Because the new generation AEDs have failed to demonstrate improved effectiveness as monotherapy, old generation AEDs such as carbamazepine and valproate remain drugs of first choice for partial and generalised seizures, respectively. However, there are special situations and populations where a new AED may be a reasonable first line drug. These include vigabatrin in West syndrome associated with tuberous sclerosis, lamotrigine as alternative to valproate in idiopathic generalised seizures in women of childbearing potential and lamotrigine for the treatment of epilepsy in the elderly population. The role of the new generation AEDs is likely to become more prominent as more experience is gained.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adab N, Jacoby A, Smith D, Chadwick D (2001) Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 70:15–21

    Article  CAS  PubMed  Google Scholar 

  2. Arroyo SA, Sander JWAS (1999) Carbamazepine in comparative trials. Pharmacokinetic characteristics too often forgotten. Neurology 53:1170–1174

    CAS  PubMed  Google Scholar 

  3. Bauer J, Isojärvi JIT Herzog AG, et al. (2002) Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. J Neurol Neurosurg Psychiatry 73:121–125

    Article  CAS  PubMed  Google Scholar 

  4. Bauer J, Jarre A, Klingmuller D, Elger CE (2000) Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 41:163–167

    Article  CAS  PubMed  Google Scholar 

  5. Bill P, Vigonius U, Pohlmann H, Guerreiro C, Kochen S, Saffer D, Moore A (1997) A double-blind, controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 27:195–204

    Article  CAS  PubMed  Google Scholar 

  6. Brodie MJ, Chadwick DW, Anhut H, et al. (2002) Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 43:993–1000

    Article  CAS  PubMed  Google Scholar 

  7. Brodie MJ, Overstall PW, Giorgi L, The UK Lamotrigine Elderly Study Group (1999) Multicentre, randomized comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 37:81–87

    Article  CAS  PubMed  Google Scholar 

  8. Brodie MJ, Richens A, Yuen AW (1995) Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 345:476–479

    Article  CAS  PubMed  Google Scholar 

  9. Canger R, Battino D, Canevini MP, et al. (1999) Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 40:1231–1236

    CAS  PubMed  Google Scholar 

  10. Chadwick DW, Anhut H, Greiner MJ, et al. (1998) A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945–77. Neurology 51:1282–1288

    CAS  PubMed  Google Scholar 

  11. Chadwick D, for the Vigabatrin European Monotherapy Study Group (1999) Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet 354:13–19

    Article  CAS  PubMed  Google Scholar 

  12. Chiron C, Dumas C, Jambaqué I, et al. (1997) Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 26:389–395

    Article  CAS  PubMed  Google Scholar 

  13. Christe W, Kramer G, Vigonius U, Pohlmann H, Steinhoff BJ, Brodie MJ, Moore A (1997) A double-blind, controlled clinical trial of oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 26:451–460

    Article  CAS  PubMed  Google Scholar 

  14. Craig J, Russel A, Parsons L, Robertson P, Morrison P, Waddell R, Morrow J (2002) The UK epilepsy and pregnancy registrer: update of results 1996–2002. Abstract Epilepsia 43:56

    Google Scholar 

  15. Dam M, Ekberg R, Loyning Y, Waltimo O, Jacobsen K (1989) A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 3:70–77

    Article  CAS  PubMed  Google Scholar 

  16. Eke T, Talbot JF, Lawden MC (1997) Severe persistent visual field constriction associated with vigabatrin. BMJ 314:180–181

    CAS  PubMed  Google Scholar 

  17. Elwes RDC, Johnson AL, Shorvon SD, Reynolds EH (1984) The prognosis for seizure control in newly diagnosed epilepsy. New Engl J Med 311:944–947

    CAS  PubMed  Google Scholar 

  18. Gaily E (1997) Minor Anomalies and Effects on Psychomotor Development Associated with Maternal Use of Antiepileptic Drugs. In: Tomson T, Gram L, Sillanpää M, Johannessen SI (eds) Epilepsy and Pregnancy. Wrightson Biomedical Publishing Ltd, Petersfield, pp 63–70

  19. Guberman A (1999) Hormonal contraception and epilepsy. Neurology 53 (Suppl 1):S38–S40

    CAS  PubMed  Google Scholar 

  20. Guerreiro M, Vigonius U, Pohlmann H, Manreza M, Fejerman N, Antoniuk S, Moore A (1997) A double-blind, controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 27:205–213

    Article  CAS  PubMed  Google Scholar 

  21. Heller AJ, Chesterman P, Elwes RDC, Crawford P, Chadwick D, Johnson AL, Reynolds EH (1995) Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: A randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 58:44–50

    CAS  PubMed  Google Scholar 

  22. Holmes LB, Harvey EA, Coull BA, et al. (2001) The teratogenicity of anticonvulsant drugs. N Engl J Med 344:1132–1138

    Article  CAS  PubMed  Google Scholar 

  23. Isojärvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla VV (1996) Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 39:579–584

    PubMed  Google Scholar 

  24. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV (1993) Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 329:1383–1388

    Article  PubMed  Google Scholar 

  25. Isojärvi JI, Rättya J, Myllyla VV, et al. (1998) Valproate, lamotrigine, and insulinmediated risks in women with epilepsy. Ann Neurol 43:446–451

    PubMed  Google Scholar 

  26. Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Riekkinen PJ (1995) Vigabatrin versus carbamazepine monotherapy in patients with newly diagnosed epilepsy: A randomized controlled study. Arch Neurol 52:989–996

    CAS  PubMed  Google Scholar 

  27. Kalviainen R, Nousiainen I, Mantyjarvi M, et al. (1999) Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 53:922–926

    CAS  PubMed  Google Scholar 

  28. Kaneko S, Battino D, Andermann E, et al. (1999) Congenital malformations due to antiepileptic drugs. Epilepsy Res 33:145–158

    Article  CAS  PubMed  Google Scholar 

  29. Kraemer G (2000) Epilepsy in the Elderly: Clinical Aspects and Pharmacotherapy, Georg Thieme Verlag, Stuttgart

    Google Scholar 

  30. Krauss GL, Simmonds-O’Brien E, Campbell M (1995) Successful treatment of seizures and porphyria with gabapentin. Neurology 45:594–595

    CAS  PubMed  Google Scholar 

  31. Kwan P, Brodie M (2000) Early identification of refractory epilepsy. N Engl J Med 342:314–319

    Article  CAS  PubMed  Google Scholar 

  32. Marson AG, Chadwick DW (2001) New drug treatments for epilepsy. J Neurol Neurosurg Psychiatry 70:143–148

    Article  CAS  PubMed  Google Scholar 

  33. Marson AG, Kadir ZA, Hutton LJ, Chadwick DW (1997) The new antiepileptic drugs: A systematic review of their efficacy and tolerability. Epilepsia 38:859–880

    CAS  PubMed  Google Scholar 

  34. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, Williamson PD, Treiman DM, McNamara JO, McCutchen CB, Homan R, Crill WE, Lubozyuski MF, Rosenthal NP, Mayersdorf A (1985) Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 313:145–151

    CAS  PubMed  Google Scholar 

  35. Patsalos PN, Fröscher W, Pisani F, van Rein CM (2002) Importance of drug interactions in epilepsy therapy. Epilepsia 43:365–385

    Article  CAS  PubMed  Google Scholar 

  36. Pennell PB, Ogaily MS, Macdonald RL (1995) Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology 45:456–460

    CAS  PubMed  Google Scholar 

  37. Perucca E, Beghi E, Dulac O, Shorvon S, Tomson T (2000) Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res 41:107–139

    Article  CAS  PubMed  Google Scholar 

  38. Perucca E, Dulac O, Shorvon S, Tomson T (2001) Harnessing the clinical potential of antiepileptic drug therapy: Dosage optimisation. CNS Drugs 15:609–621

    CAS  PubMed  Google Scholar 

  39. Perucca E (1996) Principles of drug treatment In: Shorvon SD,Dreifuss F, Fish D, Thomas D (eds) The Treatment of Epilepsy. Blackwell Science, Oxford, pp 152–168

    Google Scholar 

  40. Perucca E, Tomson T (1999) Monotherapy trials with the new antiepileptic drugs. Study designs, practical relevance and ethical implications. Epilepsy Res 33:247–262

    Article  CAS  PubMed  Google Scholar 

  41. Ramsay RE (1998) Response to treatment and adverse drug effects in the elderly. Epilepsy in The Elderly: Current Concepts in Understanding and Treatment, American Epilepsy Society, CME Monograph, pp 59–64

    Google Scholar 

  42. Ramsay RE, Rowan AJ, Slater JD, et al. (1994) Effect of age on epilepsy and its treatment: results from the VA Cooperative Study. Epilepsia 35(Suppl 8):91

    Google Scholar 

  43. Sabers A, Öhman I, Christensen J, Tomson T (2003) Oral contraceptives reduce lamotrigine plasma levels. Neurology 26; 61(4):570–571

    CAS  Google Scholar 

  44. Sachdeo RC, Reife RA, Lim P, Pledger G (1997) Topiramate monotherapy for partial onset seizures. Epilepsia 38:294–300

    CAS  PubMed  Google Scholar 

  45. Samrén B, van Duijn C, Christiaens GC, Hofman A, Lindhout D (1999) Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 46:739–746

    Article  PubMed  Google Scholar 

  46. Samrén B, van Duijn C,Koch S, Hiilesmaa VK, Klepel H, et al. (1997) Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 38:981–990

    PubMed  Google Scholar 

  47. Tanganelli P, Regesta G (1996) Vigabatrin vs carbamazepine monotherapy in newly diagnosed focal epilepsy: A randomized response conditional crossover study. Epilepsy Res 25:257–262

    Article  CAS  PubMed  Google Scholar 

  48. Tomson T, Kennebäck G (1997) Arrhythmia, heart rate variability, and antiepileptic drugs. Epilepsia 38(Suppl 11):S48–S51

    Google Scholar 

  49. Wallace H, Shorvon S, Tallis R (1998) Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2.052.922 and age-specific fertility rates of women with epilepsy. Lancet 352:1970–1973

    Article  CAS  PubMed  Google Scholar 

  50. Wide K, Winbladh B, Källén B (2002) Major congenital malformations after intrauterine exposure to antiepileptic drugs especially carbamazepine and valproic acid. Abstract Epilepsia 43:159

    Google Scholar 

  51. Willmore LJ (1995) The effect of age on pharmacokinetics of antiepileptic drugs. Epilepsia 36(Suppl 5):S14–S21

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Neurology, Karolinska Hospital, 17176, Stockhohn, Sweden

    Torbjörn Tomson

Authors
  1. Torbjörn Tomson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Torbjörn Tomson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tomson, T. Drug selection for the newly diagnosed patient: When is a new generation antiepileptic drug indicated?. J Neurol 251, 1043–1049 (2004). https://doi.org/10.1007/s00415-004-0344-0

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-004-0344-0

Key words

Search

Navigation